Low dose radioactive iodine-131 (RAI) has been widely reported in the treatment of patients
with differentiated thyroid cancer (DTC) since 1970′ s. However, the clinical outcomes …

Objective: Remnant ablation with radioactive iodine (I-131) is a successful form of treatment
that aims to destroy the remaining residual tissue and/or metastatic tissue after total …

Objectives Currently, little is known about the prognostic significance of achieving successful
ablation with the first dosage of I-131 in patients with differentiated thyroid cancer. This study …

Objective To investigate predictors for successful ablation and disease-free status after high-
dose radioiodine therapy in patients with differentiated thyroid cancer. Methods We enrolled …

Aim We evaluated the efficacy of two doses of I-131 (2220 MBq versus 3700 MBq) after
thyroid hormone withdrawal for thyroid remnant ablation postoperatively in patients with …

Low‐risk (LR) differentiated thyroid cancer (DTC) patients should be ablated or not, albeit,
with small dose of radioiodine is highly controversial. We hypothesized that those LR DTC …

The main approach to differentiated thyroid cancer (DTC) therapy is still empiric, consisting
of the administration of fixed activities. Repeated treatments, however, may have a stunning …

Objective To determine the success of ablative treatment using fixed high doses of 131 I in
patients with thyroid cancer. Methods A retrospective study was conducted on 274 patients …

Background: The utility of radioiodine (RAI) scans prior to 131I ablation is controversial. The
objective of this study was to evaluate the utility of RAI scans prior to 131I ablation in patient …

Objective The efficacy of low-dose radioiodine therapy (RIT) for intermediate-risk or high-risk
differentiated thyroid cancer (DTC) patients is controversial. Because of the country's …